Skip to Content

RemeGenix Inc RGXX

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

RemeGenix Inc is a development stage biotechnology company. It commercialize disease-altering therapies to prevent and treat Alzheimer's disease. The company's pipeline products include MoBA and NoMAD. It is developing technologies for the treatment of Alzheimer disease (AD), dementia and cognitive decline.

4800 Montgomery Lane, Suite 800
Bethesda, MD, 20814
T +1 518 302-1515
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Dec 31, 2013
Stock Type